Truist keeps a Buy rating and $10 price target on OmniAb (OABI) but notes that the stock should be up following the initial phase 1 clinical trial data from Immunovant (IMVT) on IMVT-1402. Omniab is seen as a key beneficiary as they helped develop Batoclimab and IMVT-1402 using their technology and is entitled to receive royalties on sales, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OABI: